Background:  SCGB3A1/Uteroglobin proteins (UGRPs) are members of the uteroglobin/Clara cell secretory protein family, officially termed secretoglobins, that bind specifically to progesterone with high affinity. UGRP functions to regulate the concentration of progesterone that is targeting the blastocyst. UGRP2, also referred to as high in normal-1 (HIN-1) or secretoglobin 3A1, acts as a potential growth inhibitory cytokine and is highly expressed in the human trachea, followed by salivary gland, lung and mammary gland. Expression of UGRP2 is increased by retinoic acid, thereby causing mucinous differentiation in primary human bronchial epithelial cells. UGRP2 may also have a role in regulating the terminally differentiated proximal epithelial airway. UGRP2 expression is enhanced by interleukin (IL)-4 and IL-13 through Stat6 binding to the proximal Statbinding element that resides in the promoter of the UGRP2 gene. Mutations in the UGRP2 gene, especially silencing with methylation, are found in the majority of breast carcinomas.

Description: Rabbit polyclonal to SCGB3A1

Immunogen: KLH conjugated synthetic peptide derived from SCGB3A1

Specificity:  ·Reacts with Human, Mouse and Rat.

·Isotype: IgG

Application:  ·Western blotting: 1/100-500. Predicted Mol wt: 10 kDa;

·Immunohistochemistry (Paraffin/frozen tissue section): 1/100-200;

·Immunocytochemistry: 1/100;

·Immunoprecipitation: 1/50;

·ELISA: 1/500;

·Optimal working dilutions must be determined by the end user.